NovoTTF-100L: Phase II data

An open-label, Swiss Phase II trial in 42 patients with locally advanced and metastatic NSCLC showed that NovoTTF-100L in combination with Alimta pemetrexed led to a median overall survival (OS) of 13.8 months vs. a historical OS of 8.3 months for Alimta alone. Median progression-free survival (PFS) was 22-28 weeks for the combination therapy vs. a historical PFS of 12 weeks for Alimta alone. Additionally, 57% of patients treated with NovoTTF-100L plus Alimta were alive at 1 year vs. 30% for the historical control group. Patients received NovoTTF-100L for 12 hours per day in combination with Alimta every 3 weeks until disease progression. Data were presented at the European Society for Medical Oncology meeting in Milan. ...